| Citation: |
LI Ying, YIN Haoyuan, PAN Li, FENG Lei. Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 418-423. DOI: 10.3971/j.issn.1000-8578.2021.20.0997
|
In recent years, tumor immunotherapy with immune checkpoint as the target has attracted much attention because of its remarkable efficacy. However, with the application of immune-checkpoint inhibitors (ICIs), more and more immune-related adverse events (irAEs) have been reported. IrAEs impose an additional risk of death on tumor patients treated with ICIs, limiting the widespread use of ICIs. To help patients actively prevent irAEs, biomarkers with the predictive value of irAEs are of great significance. This paper reviews the biomarkers with predictive value for irAEs from the aspects of serology, genetics and microbiology.
| [1] |
Judd J, Zibelman M, Handorf E, et al. Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors[J]. Oncologist, 2017, 22(10): 1232-1237. doi: 10.1634/theoncologist.2017-0133
|
| [2] |
Mcgonagle D, Bragazzi NL, Amital H, et al. Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival[J]. Autoimmun Rev, 2020, 19(2): 102456. doi: 10.1016/j.autrev.2019.102456
|
| [3] |
Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J]. N Engl J Med, 2018, 378(2): 158-168. doi: 10.1056/NEJMra1703481
|
| [4] |
Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2019, 17(3): 255-289. doi: 10.6004/jnccn.2019.0013
|
| [5] |
Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy[J]. J Clin Oncol, 2017, 35(7): 709-717. doi: 10.1200/JCO.2016.68.2005
|
| [6] |
Roberts J, Ennis D, Hudson M, et al. Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort[J]. Autoimmun Rev, 2020, 19(8): 102595. doi: 10.1016/j.autrev.2020.102595
|
| [7] |
Michot JM, Lazarovici J, Tieu A, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?[J]. Eur J Cancer, 2019, 122: 72-90. doi: 10.1016/j.ejca.2019.07.014
|
| [8] |
Khan S, Khan SA, Luo X, et al. Immune dysregulation in cancer patients developing immune-related adverse events[J]. Br J Cancer, 2019, 120(1): 63-68. doi: 10.1038/s41416-018-0155-1
|
| [9] |
Oyanagi J, Koh Y, Sato K, et al. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab[J]. Lung Cancer, 2019, 132: 107-113. doi: 10.1016/j.lungcan.2019.03.020
|
| [10] |
Valpione S, Pasquali S, Campana LG, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade[J]. J Transll Med, 2018, 16(1): 94. doi: 10.1186/s12967-018-1467-x
|
| [11] |
Tanaka R, Okiyama N, Okune M, et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity[J]. J Dermatol Sci, 2017, 86(1): 71-73. doi: 10.1016/j.jdermsci.2016.12.019
|
| [12] |
Patel SAA, Gooderham NJ. IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b[J]. Mol Cancer Res, 2015, 13(11): 1502-1508. doi: 10.1158/1541-7786.MCR-15-0147
|
| [13] |
Jeurling S, Cappelli L. Treatment of immune checkpoint inhibitor-induced inflammatory arthritis[J]. Curr Opin Rheumatol, 2020, 32(3): 315-320. doi: 10.1097/BOR.0000000000000701
|
| [14] |
Tarhini A A, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma[J]. J Immunother Cancer, 2015, 3: 39. doi: 10.1186/s40425-015-0081-1
|
| [15] |
Kim ST, Bittar M, Kim HJ, et al. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare[J]. J Immunother Cancer, 2019, 7(1): 126. doi: 10.1186/s40425-019-0597-x
|
| [16] |
Fujimura T, Sato Y, Tanita K, et al. Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study[J]. Oncotarget, 2018, 9(21): 15542-15551. doi: 10.18632/oncotarget.24509
|
| [17] |
Schoenfeld JD, Nishino M, Severgnini M, et al. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features[J]. J Immunother Cancer, 2019, 7(1): 112. doi: 10.1186/s40425-019-0583-3
|
| [18] |
Bridge JA, Lee JC, Daud A, et al. Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer[J]. Front Med (Lausanne), 2018, 5: 351. http://www.researchgate.net/publication/329594537_Cytokines_Chemokines_and_Other_Biomarkers_of_Response_for_Checkpoint_Inhibitor_Therapy_in_Skin_Cancer
|
| [19] |
Lim S Y, Lee JH, Gide TN, et al. Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy[J]. Clin Cancer Res, 2019, 25(5): 1557-1563. doi: 10.1158/1078-0432.CCR-18-2795
|
| [20] |
Osorio JC, Ni A, Chaft JE, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer[J]. Ann Oncol, 2017, 28(3): 583-589. doi: 10.1093/annonc/mdw640
|
| [21] |
Kimbara S, Fujiwara Y, Iwama S, et al. Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab[J]. Cancer Sci, 2018, 109(11): 3583-3590. doi: 10.1111/cas.13800
|
| [22] |
Stamatouli AM, Quandt Z, Perdigoto AL, et al. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors[J]. Diabetes, 2018, 67(8): 1471-1480. doi: 10.2337/dbi18-0002
|
| [23] |
Sakakida T, Ishikawa T, Chihara Y, et al. Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies[J]. Clin Transl Oncol, 2020, 22(6): 919-927. doi: 10.1007/s12094-019-02214-8
|
| [24] |
Von Itzstein MS, Khan S, Gerber DE. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis[J]. Clin Chem, 2020, 66(6): 779-973. doi: 10.1093/clinchem/hvaa081
|
| [25] |
Ali HO, Bomze D, Ring SS, et al. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors[J]. J Am Acad Dermatol, 2020, 82(4): 854-861. doi: 10.1016/j.jaad.2019.08.045
|
| [26] |
Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival[J]. Ann Oncol, 2013, 24(6): 1697-1703. doi: 10.1093/annonc/mdt027
|
| [27] |
Moreira A, Leisgang W, Schuler G, et al. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy[J]. Immunotherapy, 2017, 9(2): 115-121. doi: 10.2217/imt-2016-0138
|
| [28] |
Bernard TA, Jeanville P, Champiat S, et al. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies[J]. Eur J Cancer, 2017, 81: 135-137. doi: 10.1016/j.ejca.2017.05.017
|
| [29] |
Kizawa R, Miura Y, Oda Y, et al. Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events(irAEs)[J]. Ann Oncol, 2019, 30, Supp 5: v508. http://www.researchgate.net/publication/336195359_1245PEosinophilia_during_treatment_of_immune_checkpoint_inhibitors_ICIs_predicts_succeeding_onset_of_immune-related_adverse_events_irAEs/download
|
| [30] |
Nakamura Y, Tanaka R, Maruyama H, et al. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies[J]. Jpn J Clin Oncol, 2019, 49(5): 431-437. doi: 10.1093/jjco/hyy201
|
| [31] |
Diehl A, Yarchoan M, Hopkins A, et al. Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors[J]. Oncotarget, 2017, 8(69): 114268-114280. doi: 10.18632/oncotarget.23217
|
| [32] |
Fujisawa Y, Yoshino K, Otsuka A, et al. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab[J]. J Dermatol Sci, 2017, 88(2): 225-231. doi: 10.1016/j.jdermsci.2017.07.007
|
| [33] |
Pavan A, Calvetti L, Dal MA, et al. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors[J]. Oncologist, 2019, 24(8): 1128-1136. doi: 10.1634/theoncologist.2018-0563
|
| [34] |
Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors[J]. Cancer Immunol Immunother, 2020, 69(9): 1813-1822. doi: 10.1007/s00262-020-02585-w
|
| [35] |
Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J]. Ann Oncol, 2017, 28(6): 1368-1379. doi: 10.1093/annonc/mdx108
|
| [36] |
Oh DY, Cham J, Zhang L, et al. Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire[J]. Cancer Res, 2017, 77(6): 1322-1330. doi: 10.1158/0008-5472.CAN-16-2324
|
| [37] |
Subudhi S K, Aparicio A, Gao J, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities[J]. Proc Natl Acad Sci U S A, 2016, 113(42): 11919-11924. doi: 10.1073/pnas.1611421113
|
| [38] |
Ali OH, Berner F, Bomze D, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors[J]. Eur J Cancer, 2019, 107: 8-14. doi: 10.1016/j.ejca.2018.11.009
|
| [39] |
Cappelli LC, Dorak MT, Bettinotti MP, et al. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis[J]. Rheumatology (Oxford), 2019, 58(3): 476-480. doi: 10.1093/rheumatology/key358
|
| [40] |
Munakata W, Ohashi K, Yamaauchi N, et al. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma[J]. Int J Hematol, 2017, 105(3): 383-386. doi: 10.1007/s12185-016-2101-4
|
| [41] |
Sakurai K, Niiisuma S, Sato R, et al. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab[J]. Tohoku J Exp Med, 2018, 244(1): 33-40. doi: 10.1620/tjem.244.33
|
| [42] |
Queirolo P, Dozin B, Morabito A, et al. CTLA-4 gene variant -1661A > G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab[J]. Eur J Cancer, 2018, 97: 59-61. doi: 10.1016/j.ejca.2018.04.005
|
| [43] |
Bins S, Basak EA, El Bouazzaoui S, et al. Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients[J]. Br J Cancer, 2018, 118(10): 1296-1301. doi: 10.1038/s41416-018-0074-1
|
| [44] |
Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis[J]. Nat Commun, 2016, 7: 10391. doi: 10.1038/ncomms10391
|
| [45] |
Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota[J]. Proc Natl Acad Sci U S A, 2010, 107(27): 12204-12209. doi: 10.1073/pnas.0909122107
|
| [46] |
Wang T, Zheng N, Luo Q, et al. Probiotics Lactobacillus reuteri Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells[J]. Front Immunol, 2019, 10: 1235. doi: 10.3389/fimmu.2019.01235
|
| [47] |
Cortellini A, Buti S, Santini D, et al. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study[J]. Oncologist, 2019, 24(6): e327-e337. doi: 10.1136/annrheumdis-2018-EWRR2019.9
|
| [48] |
Khoja L, Day D, Wei WCT, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review[J]. Ann Oncol, 2017, 28(10): 2377-2385. doi: 10.1093/annonc/mdx286
|
| 1. |
曹海波，马晓林. 泛癌分析KCNQ1OT1与免疫特征的相关性. 山东第二医科大学学报. 2025(01): 51-55 .
| |
| 2. |
彭本钊，严首春. 鸦胆子抗肿瘤活性成分及其作用机制研究进展. 辽宁中医药大学学报. 2024(12): 213-220 .
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: